Sign In
Buy MYGN
$2.86
-2.51 (-46.74%)
At Close: Jul 31, 2026
Analysts Set Myriad Genetics, Inc. (NASDAQ:MYGN) PT at $9.44
01:32am, Sunday, 08'th Feb 2026
Myriad Genetics, Inc. (NASDAQ: MYGN - Get Free Report) has earned a consensus rating of "Hold" from the thirteen brokerages that are currently covering the firm, MarketBeat reports. Three research ana
AMH Equity Ltd Has $2.89 Million Stock Position in Myriad Genetics, Inc. $MYGN
03:20am, Sunday, 18'th Jan 2026
AMH Equity Ltd increased its holdings in Myriad Genetics, Inc. (NASDAQ: MYGN) by 33.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchang
Myriad Genetics, Inc. (MYGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
11:05pm, Wednesday, 14'th Jan 2026
Myriad Genetics, Inc. (MYGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Myriad Genetics, Inc. (NASDAQ:MYGN) Receives $10.50 Consensus Price Target from Analysts
02:16am, Wednesday, 14'th Jan 2026
Myriad Genetics, Inc. (NASDAQ: MYGN - Get Free Report) has received a consensus recommendation of "Hold" from the fourteen analysts that are covering the stock, MarketBeat reports. Two equities resear
Myriad announced select unaudited preliminary results for the 4th quarter and full year ended Dec. 31, 2025, provided full year 2026 financial guidance.
Myriad Genetics (NASDAQ:MYGN) Stock Passes Above 200 Day Moving Average – Here’s Why
03:16am, Wednesday, 07'th Jan 2026
Myriad Genetics, Inc. (NASDAQ: MYGN - Get Free Report)'s stock price passed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $6.52 and traded as hi
Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference
04:15pm, Monday, 05'th Jan 2026
SALT LAKE CITY, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Sam Raha, president and
Should Myriad Genetics Stock Stay in Your Portfolio Right Now?
09:11am, Tuesday, 30'th Dec 2025
MYGN shows growth potential from new genetic test launches and a refreshed CCC strategy, but revenue pressure from GeneSight coverage loss remains a drag.
Myriad Genetics (NASDAQ:MYGN) Share Price Passes Above 200-Day Moving Average – Here’s Why
03:17am, Tuesday, 30'th Dec 2025
Myriad Genetics, Inc. (NASDAQ: MYGN - Get Free Report)'s share price passed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $6.47 and traded as hig
Fisher Asset Management LLC Purchases 219,607 Shares of Myriad Genetics, Inc. $MYGN
04:20am, Friday, 05'th Dec 2025
Fisher Asset Management LLC lifted its position in shares of Myriad Genetics, Inc. (NASDAQ: MYGN) by 20.4% during the undefined quarter, according to the company in its most recent 13F filing with the
Why Is Myriad (MYGN) Up 8.7% Since Last Earnings Report?
12:36pm, Wednesday, 03'rd Dec 2025
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock?
Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health
04:15pm, Tuesday, 25'th Nov 2025
BOSTON and SALT LAKE CITY and FULTON, Md., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Clairity, Myriad Genetics, Inc. (NASDAQ: MYGN), and MagView, today announced a joint collaboration in an effort to ident
969,127 Shares in Myriad Genetics, Inc. $MYGN Acquired by Acadian Asset Management LLC
03:15am, Friday, 14'th Nov 2025
Acadian Asset Management LLC bought a new position in Myriad Genetics, Inc. (NASDAQ: MYGN) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
09:00am, Tuesday, 11'th Nov 2025
SALT LAKE CITY, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced Myriad management will particip
Myriad Genetics: Downgrading To "Hold" Rating On Break-Even Q3 Earnings
01:36pm, Wednesday, 05'th Nov 2025
Myriad Genetics (MYGN) is downgraded from a "Buy" to "Hold" due to flat Q3 2025 earnings and limited near-term revenue growth. MYGN's Hereditary Cancer Test and Prolaris segments show volume growth, b
